posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.
Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
La source: MarketWatch - 🏆 3. / 97 Lire la suite »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
La source: MarketWatch - 🏆 3. / 97 Lire la suite »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
La source: NBCLA - 🏆 319. / 59 Lire la suite »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
La source: NBCNewYork - 🏆 270. / 63 Lire la suite »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
La source: MarketWatch - 🏆 3. / 97 Lire la suite »